C
GDTC
vs
S&P 500
S&P 500
Over the past 12 months, GDTC has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's +18% growth.
Stocks Performance
GDTC vs S&P 500
Performance Gap
GDTC vs S&P 500
Performance By Year
GDTC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CytoMed Therapeutics Ltd
Glance View
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 27 full-time employees The company went IPO on 2023-04-14. The firm is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. The company is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
